This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, L. Articles by Greipp, P. R. Search for Related Content PubMed PubMed Citation Articles by Wang, L. Articles by Greipp, P. R.

Proteasome β Subunit Pharmacogenomics: Gene Resequencing and Functional Genomics

Authors' Affiliations: ¹ Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics and Departments of ² Internal Medicine, ³ Health Sciences Research, and ⁴ Biochemistry and Molecular Biology, Mayo Clinic, Mayo Medical School, Rochester, Minnesota

Requests for reprints: Liewei Wang, Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-5264; Fax: 507-507-284-4455; E-mail: wang.liewei{at}mayo.edu.

Purpose: The proteasome is a multisubunit cellular organelle that functions as a nonlysosomal threonine protease. Proteasomes play a critical role in the degradation of proteins, regulating a variety of cellular processes, and they are also the target for antineoplastic proteasome inhibitors. Genetic variation in proteasome subunits could influence both proteasome function and response to drug therapy.

Experimental Design: We resequenced genes encoding the three active proteasome β subunits using 240 DNA samples from four ethnic groups and the β5 subunit gene in 79 DNA samples from multiple myeloma patients who had been treated with the proteasome inhibitor bortezomib. Resequencing was followed by functional studies of polymorphisms identified in the coding region and 3'-flanking region (3'-FR) of PSMB5, the gene encoding the target for clinically useful proteasome inhibitors.

Results: Resequencing of 240 DNA samples identified a series of novel ethnic-specific polymorphisms that are not represented in public databases. The PSMB5 3'-FR 1042 G allele significantly increased transcription during reporter gene studies, observations confirmed by genotype-phenotype correlations between single nucleotide polymorphisms (SNP) in PSMB5 and mRNA expression in the 240 lymphoblastoid cell lines from which the resequenced DNA was obtained. Studies with patient DNA samples identified additional novel PSMB5 polymorphisms, including a SNP and an insertion in the 3'-FR. Reporter-gene studies indicated that these two novel polymorphisms might decrease transcription.

Conclusions: These results show that nonsynonymous coding SNPs in the PSMB5 gene did not show significant effects on proteasome activity, but SNPs did influence transcription. Future studies might focus on regulatory region polymorphisms.

This article has been cited by other articles:

				S. Kumar and S. V. Rajkumar Many facets of bortezomib resistance/susceptibility Blood, September 15, 2008; 112(6): 2177 - 2178. [Full Text] [PDF]